Skip to content

US · IMRN · BIOTECHNOLOGY

Immuron Limited (IMRN) intrinsic value and stock valuation

$0.90as of 2026-11-21 · Mkt cap 6.65M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Immuron Limited DCF and intrinsic value

InvestorsCraft values IMRN with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from IMRN’s statements →

Immuron Limited Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Carlton, VIC 3053 immuron.com.au

How the business is doing

Fiscal 2011–2025, USD

Revenue
$7.29M+23.7% 5y CAGRd
20112025
Net income
-$-5.22M
20112025
Free cash flow
-$-6.14M
20112025
Total equity
$8.03M+7.3% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$7.29M$4.9M$1.8M$770K$150K
Operating income-$-5.34M-$-5.8M-$-3.57M-$-2.87M-$-8.38M
Net income-$-5.22M-$-6.94M-$-3.79M-$-2.85M-$-8.38M
EPSd-$-904.68K-$-1.22M-$-666.08K-$-500.88K-$-1.52M
Operating cash flow-$-6.14M-$-5.88M-$-2.49M-$-3.13M-$-3.05M
Capital expenditure-$0.00-$0.00-$-10K-$-10K-$0.00
Free cash flow-$-6.14M-$-5.88M-$-2.5M-$-3.14M-$-3.05M
Total assets$10.1M$15.6M$22M$24.9M$27.1M
Total debt$120K$170K$190K$210K$20K
Net debt-$-2.71M-$-11.48M-$-16.97M-$-21.9M-$-25.03M
Total equity$8.03M$12.7M$19.6M$23.2M$25.9M
Cash and short-term investments$5.87M$11.7M$19M$22.1M$25.1M
Income statement
20252024202320222021
Revenue$7.29M$4.9M$1.8M$770K$150K
Cost of revenue$2.52M$1.57M$60K$240K$810K
Gross profit$4.77M$3.34M$1.74M$520K-$-670K
Research and development expenses$3.6M$5.38M$2.59M$660K$1.37M
Selling, general and administrative expenses$7.94M$6.59M$5.15M$3.94M$6.38M
Other expenses-$-1.42M-$-2.82M-$-2.43M-$-1.21M-$-30K
Operating expenses$10.1M$9.14M$5.31M$3.39M$7.71M
Cost and expenses$12.6M$10.7M$5.37M$3.64M$8.53M
Interest income$140K$330K$120K$20K$10K
Interest expense$10K$10K$10K$10K$10K
Depreciation and amortization$50K$50K$50K$30K$10K
Ebitda-$-5.31M-$-5.17M-$-3.36M-$-3.09M-$-7.95M
Operating income-$-5.34M-$-5.8M-$-3.57M-$-2.87M-$-8.38M
Total other income/expenses, net$130K-$-1.14M-$-220K$20K-$0.00
Income before tax-$-5.22M-$-6.94M-$-3.79M-$-2.85M-$-8.38M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-5.22M-$-6.94M-$-3.79M-$-2.85M-$-8.38M
Weighted average shares outstanding$5.77M$5.7M$5.69M$5.69M$5.53M
Weighted average diluted shares outstanding$5.77M$5.7M$5.69M$5.69M$5.53M
Balance sheet
20252024202320222021
Cash and short-term investments$5.87M$11.7M$19M$22.1M$25.1M
Net receivables$790K$1.39M$420K$660K$330K
Inventory$1.77M$1.58M$840K$330K$290K
Total current assets$9.98M$14.7M$20.4M$23.7M$25.8M
Property, plant and equipment, net$110K$150K$200K$230K$30K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$160K$0.00$0.00
Total non-current assets$110K$820K$1.58M$1.18M$1.3M
Total assets$10.1M$15.6M$22M$24.9M$27.1M
Accounts payable$1.53M$650K$790K$720K$110K
Short-term debt$50K$40K$40K$30K$20K
Deferred revenue$0.00$0.00$700K$0.00$0.00
Total current liabilities$1.97M$2.7M$2.22M$1.5M$1.12M
Long-term debt$70K$130K$150K$180K$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$90K$140K$150K$180K$40K
Capital lease obligations$120K$170K$190K$210K$20K
Total liabilities$2.06M$2.84M$2.37M$1.68M$1.16M
Common stock$88.9M$88.5M$88.4M$88.4M$88.4M
Retained earnings-$-82.48M-$-78.97M-$-72.06M-$-68.43M-$-65.93M
Accumulated other comprehensive income (loss)$1.64M$3.17M$3.24M$3.17M$3.47M
Total equity$8.03M$12.7M$19.6M$23.2M$25.9M
Total investments$3.04M$0.00$1.99M$0.00$0.00
Total debt$120K$170K$190K$210K$20K
Net debt-$-2.71M-$-11.48M-$-16.97M-$-21.9M-$-25.03M
Cash flow statement
20252024202320222021
Net income-$-5.22M-$-6.94M-$-3.79M-$-2.85M-$-6.25M
Depreciation and amortization$50K$0.00$50K$30K$30K
Stock-based compensation$300K$0.00$230K$90K$0.00
Change in working capital-$-520K-$-970K$1.4M-$-270K$1.14M
Accounts receivable-$-560K-$-960K$230K-$-340K$20K
Inventory$480K-$-190K-$-780K$280K$720K
Accounts payable$0.00$0.00$30K$290K$440K
Net cash provided by operating activities-$-6.14M-$-5.88M-$-2.49M-$-3.13M-$-3.05M
Investments in property, plant and equipment$0.00-$0.00-$-10K-$-10K-$0.00
Acquisitions, net$0.00$0.00-$-2.73M$0.00$0.00
Net cash used for investing activities-$-2.9M$330K-$-2.74M$10K-$0.00
Common stock issued$400K$20K$0.00$0.00$19.8M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$200K$0.00-$-40K-$-40K$19.8M
Net change in cash-$-8.83M-$-5.5M-$-4.95M-$-2.94M$21.8M
Cash at end of period$2.83M$11.7M$17.2M$22.1M$25.1M
Operating cash flow-$-6.14M-$-5.88M-$-2.49M-$-3.13M-$-3.05M
Capital expenditure-$0.00-$0.00-$-10K-$-10K-$0.00
Free cash flow-$-6.14M-$-5.88M-$-2.5M-$-3.14M-$-3.05M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Immuron Limited

        Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and other international markets. The company's activities are structured into two key segments: Research and Development, and Hyperimmune Products. Currently, Immuron markets two key products. Travelan is an over-the-counter (OTC) medicine that helps reduce the risk of traveler's diarrhea and lessens symptoms of minor gastrointestinal issues, while also serving as a dietary supplement for digestive tract protection. Its second product, Protectyn, is an immune supplement formulated to support healthy digestive function and liver health. In its pipeline, an advanced formulation of Travelan (IMM-124E) is undergoing Phase III clinical trials. This variant is being developed not only to further reduce the risk of traveler's diarrhea but also for its potential anti-viral activity against SARS-CoV-2. Another pipeline candidate, IMM-529, is in clinical development with a focus on treating recurrent Clostridium difficile infections. Immuron maintains strategic collaborations, including a research agreement with the Naval Medical Research Center to develop and clinically assess a therapeutic targeting Campylobacter and ETEC infections. Additionally, it has a collaboration with the Walter Reed Army Institute of Research aimed at creating an oral therapeutic for shigellosis. Established in 1994, Immuron Limited is headquartered in Carlton, Australia.

        CEO
        Steven George Lydeamore
        Employees
        7
        Beta
        0.51

        Explore

        Frequently asked questions

        What is the intrinsic value of Immuron Limited (IMRN)?

        InvestorsCraft does not currently publish an intrinsic value for IMRN. How the IC value is calculated.

        Is IMRN undervalued?

        InvestorsCraft does not publish an undervaluation signal for IMRN at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.